

Special Issue

Radiation Therapy in Lymphoma

Message from the Guest Editors

We are pleased to announce the Special Issue of *Cancers* on "Radiation Therapy in Lymphoma". Radiotherapy can be curative in patients with localized indolent non-Hodgkin lymphoma, or it can contribute to curation as consolidation after (immuno-) chemotherapy in aggressive non-Hodgkin lymphoma or in Hodgkin's disease. Radiation planning systems and the technical possibilities of radiation treatment on linear accelerators have developed immensely in recent times. In parallel, the development of newly approved chemotherapeutic agents and immunotherapeutic agents is contributing to increasingly effective multimodal therapy concepts with simultaneously fewer side effects. In parallel, there is a trend toward lower radiation doses and overall shorter treatment series. In this Special Issue, original research articles and reviews are welcome. This Special Issue will highlight the treatment outcomes and survival rates of Hodgkin and non-Hodgkin lymphoma in adolescents and adults, as well as the state of the art of current radiation treatment approaches and novel radiotherapy techniques. We look forward to receiving your contributions.

Guest Editors

Prof. Dr. Hans Theodor Eich

Department of Radiation Oncology, University Hospital of Muenster, Muenster, Germany

Dr. Gabriele Reinartz

Department of Radiation Oncology, University Hospital of Muenster, D-48149 Muenster, Germany

Deadline for manuscript submissions

closed (30 June 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/144201

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)